KalVista Pharmaceuticals (KALV) Interest Expenses (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Interest Expenses of $3.5 million in Q3 2025, up 3902.27% quarter-over-quarter from $88000.0 in Q1 2016.
KalVista Pharmaceuticals' Interest Expenses history runs 4 years deep, the most recent figure standing at $3.5 million for Q3 2025.
- In Q3 2025, Interest Expenses changed N/A year-over-year to $3.5 million; the TTM figure through Jul 2025 stood at $3.5 million (changed N/A YoY), while the FY2025 annual figure was $5.8 million, changed N/A from the prior year.
- Interest Expenses came in at $3.5 million for Q3 2025 at KalVista Pharmaceuticals, up from $88000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $3.5 million in Q3 2025 to a low of $3.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 3.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 3.52 Mn |
| Jul 31, 2025 | 3.52 Mn |
| Mar 31, 2016 | 88,000.00 |
| Mar 31, 2016 | 88,000.00 |
| Dec 31, 2015 | 88,000.00 |
| Dec 31, 2015 | 88,000.00 |
| Sep 30, 2015 | 95,000.00 |
| Sep 30, 2015 | 95,000.00 |
| Jun 30, 2015 | 169,000.00 |
| Jun 30, 2015 | 169,000.00 |
| Mar 31, 2015 | 836,000.00 |
| Mar 31, 2015 | 836,000.00 |
| Dec 31, 2014 | 562,000.00 |
| Dec 31, 2014 | 562,000.00 |
| Sep 30, 2014 | 357,000.00 |
| Sep 30, 2014 | 357,000.00 |
| Jun 30, 2014 | 83,000.00 |
| Jun 30, 2014 | 83,000.00 |
| Mar 31, 2014 | 80,000.00 |
| Mar 31, 2014 | 80,000.00 |